ZNF512 is a sequence-specific DNA-binding transcription factor that plays a central role in constitutive heterochromatin formation at pericentric regions. The protein recognizes non-consecutive TTC triplet sequences through its zinc-finger domains, which feature atypical long linker residues providing flexibility in DNA recognition 1. Upon binding, ZNF512 directly recruits the histone methyltransferases SUV39H1 and SUV39H2 to catalyze repressive H3K9 trimethylation, initiating de novo heterochromatin formation 1. This mechanism is evolutionarily conserved across vertebrates, allowing ZNF512 from different species to target pericentric regions despite sequence variation, thereby explaining how seemingly variable pericentric sequences are targeted by conserved silencing machinery 1. Beyond its canonical heterochromatin function, ZNF512 expression changes are associated with disease progression. The protein is significantly downregulated in cervical cancer lymph node metastasis 2, and ZNF512 has been identified as a potential prognostic and metastasis-predictive biomarker 2. In lung cancer, ZNF512 expression alterations correlate with adenocarcinoma stage and prognosis, potentially functioning as a protective or risk factor depending on expression level 3. Additionally, ZNF512 was identified as a thermal-stabilized target of the histone deacetylase inhibitor panobinostat in whole blood 4, suggesting pharmacological relevance.